Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 1967648, 7 pages
https://doi.org/10.1155/2017/1967648
Research Article

MYC Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection

1Department of Hematology, The First Hospital of Jilin University, Changchun 130021, China
2Department of Pediatrics, Women and Children’s Hospital of Qingdao University, Qingdao 266000, China
3Department of Pathology Diagnosis Center, The First Hospital of Jilin University, Changchun 130021, China

Correspondence should be addressed to Ou Bai; moc.361@61iabuo

Received 2 August 2017; Revised 21 September 2017; Accepted 3 October 2017; Published 25 October 2017

Academic Editor: Carlo Visco

Copyright © 2017 Zhihe Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The aim of this study was to identify clinical adverse prognostic factors affecting overall survival (OS) of diffuse large B cell (DLBCL) patients with hepatitis B virus (HBV) infection. In this study, 30 DLBCL patients with HBV infection and 51 DLBCL patients with HBV-free were reviewed retrospectively. As of July 2016, the median follow-up period was 26.4 months (3.0~65.0 months). The median OS of patients in HBV infection group was 38.6 months, while that of patients in HBV-free group was not reached (); the median progression-free survival (PFS) of patients in HBV infection group was worse than that in HBV-free group, 18.5 months and 38.5 months (), respectively. The rate of MYC and BCL2 gene rearrangements in HBV infection group was significantly higher than that in HBV-free group, 20.0% versus 3.9% () and 23.3% versus 5.9% (), respectively. Multivariable analysis indicated that IPI (), chemotherapy regimens (), and MYC gene rearrangements () were independent adverse prognostic factors for all DLBCL patients in this study. Results demonstrated that the poor survival of DLBCL patients with HBV infection was closely involved in chemotherapy regimens, IPI, and MYC gene rearrangements.